A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M₁ receptor agonist HTL0018318 in patients with mild-to-moderate Alzheimer's disease.

While the improvement in episodic memory did not reach statistical significance, the effects observed are consistent with pre‐clinical evidence across multiple muscarinic M 1 receptor agonists, as well as previous findings in humans using the same test with the M 1 agonist GSK1034702. 33 The improvement seen with HTL0018318 specifically on the tests of attention and episod

also in 111,027 other papers